Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database

Soong, Seng Jaw; Ding, Shuo; Coit, Daniel G.; Balch, Charles M.; Gershenwald, Jeffrey E.; Thompson, John F.; Gimotty, Phyllis A.

doi:10.1245/s10434-010-1050-z

Cited by 109 publications

(112 citation statements)

References 20 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…For instance, the 10-year survival probability for a women 75 years of age with a 2.2 mm non-ulcerated CMM in the present study was 79% (76-82) compared with 60% (51-69) in the study by Soong (4). Other studies have previously found such disparities and the most probable explanation is selection bias.…”

Section: Discussioncontrasting

confidence: 68%

“…This superior non-stage effect for women has previously been found in studies with similar HR (19,20). Surprisingly, sex was not included in the final prognostic model in two of the largest published prognostic instruments based on AJCC data and from Queensland Australia respectively (3,4).…”

Section: Discussionmentioning

confidence: 56%

“…The generalised gamma (GG) distribution with three parameters was used as being previously recommended for this kind of data (4,17). As being a parametric method, estimates for 1,440 combinations of prognostic groups could be managed, even for groups with no CMM-specific deaths.…”

Section: Discussionmentioning

confidence: 99%

“…(1) Mervic suggests that adding sex, age and tumour site to the AJCCclassification could improve the prediction of an individual patient's prognosis compared to the AJCC staging system currently in use (1,2). A few prognostic instruments have been presented but some are based on a limited number of patients and others are based on selected groups of patients referred to major institutions treating CMM (3)(4)(5)(6)(7)(8)(9). Hence, former instruments have not been as generalizable as expected.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register

Lyth

Mikiver

Nielsen

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register

Lyth

Mikiver

Nielsen

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…2 A subset of tumours characterized as deep (depth of >4 mm), with ulceration or possibly those with a high tumour mitotic rate (≥1 per mm 2 ), are considered high risk for recurrence. 15 The panel recom mends that all stage II patients have a comprehensive diagnostic workup and be reviewed by a multi disciplinary team (surgical oncologist, medical oncologist and dermatopathologist) to accurately determine tumour stage and risk of melanoma recurrence. This workup should include sentinel-lymph-node biopsy, when appropriate.…”

Section: Initial Assessmentmentioning

confidence: 99%

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

et al. 2013

View full text Add to dashboard Cite

| Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

show abstract

Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma

et al. 2018

View full text Add to dashboard Cite

IMPORTANCE Early detection of melanoma is associated with improved patient outcomes. Data suggest that spouses or partners may facilitate detection of melanoma before the onset of regional and distant metastases. Less well known is the influence of marital status on the detection of early clinically localized melanoma. OBJECTIVE To evaluate the association between marital status and T stage at the time of presentation with early-stage melanoma and the decision for sentinel lymph node biopsy (SLNB) in appropriate patients. DESIGN, SETTING, AND PARTICIPANTS This retrospective, population-based study used the Surveillance, Epidemiology, and End Results database of 18 population-based registered cancer institutes. Patients with cutaneous melanoma who were at least 18 years of age and without evidence of regional or distant metastases and presented from January 1, 2010, through December 31, 2014, were identified for the study. Data were analyzed from September 27 to December 5, 2017. EXPOSURE Marital status, categorized as married, never married, divorced, or widowed. MAIN OUTCOMES AND MEASURES Clinical T stage at presentation and performance of SLNB for lesions with Breslow thickness greater than 1 mm. RESULTS A total of 52 063 patients were identified (58.8% men and 41.2% women; median age, 64 years; interquartile range, 52-75 years). Among married patients, 16 603 (45.7%) presented with T1a disease, compared with 3253 never married patients (43.0%), 1422 divorced patients (39.0%), and 1461 widowed patients (32.2%) (P < .001). Conversely, 428 widowed patients (9.4%) presented with T4b disease compared with 1188 married patients (3.3%) (P < .001). The association between marital status and higher T stage at presentation remained significant among never married (odds ratio [

show abstract

Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database

Cited by 109 publications

References 20 publications

Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register

Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma

Contact Info

Product

Resources

About